SKYE
Skye Bioscience, Inc.
Healthcare — Biotechnology
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.
None
7 analysts
$1.60
$-0.01 (-0.62%)
Target:
$7.71
(382.1%)
Price History
52-Week Range
Sign in to add SKYE to a watchlist or set price alerts.
Fundamentals
| Market Cap | $24.32M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.61 |
| EPS (TTM) | $-1.45 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -167.97% |
| Debt/Equity | 3.46 |
| Recommendation | None |
| Analyst Target | $7.71 |
| Analysts | 7 |
| Next Earnings | May 11, 2026 |
| Indexes | - |
Technical Indicators
| RSI (14) | 28.2 |
| Beta | 2.93 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $4.99 |
| 52-Week Low | $0.57 |
| 50-Day Avg | $0.80 |
| 200-Day Avg | $1.20 |
| Avg Volume | 183.2K |
| Volume | 2.6K |
Performance Analysis
BULLISHSKYE shows predominantly bullish signals based on its fundamentals and technicals.
~
Trading at 23% of its 52-week range.
+
RSI at 28.2 signals oversold conditions — a bounce may be ahead.
+
Price is above both the 50-day and 200-day moving averages — strong uptrend.
~
Wall Street consensus is "none" from 7 analysts.
+
Average analyst target of $7.71 implies 382.1% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:31 UTC
Back to Screener Export Report